Category: Insights

Many life sciences companies find themselves drowning in a sea of technology that fails to deliver a meaningful return on investment. In this white paper, we describe how companies can create a technology ecosystem that enables and enhances the work of users across the commercial organization.

The best way to create a believable and defensible forecast is to build it using a flexible, lever-based forecast model. This kind of model will allow stakeholders to run scenarios quickly and understand the impact of the assumptions that make up the forecast. We explain the keys to creating a flexible, lever-based model.

Like a coach following last year’s game plan to prepare for this year’s championship, life sciences commercial operations leaders – especially those with previous roles at established pharmaceutical companies – may be tempted to deploy their last sales force design strategy on their next product launch. If that therapy is CAR T, commercial operations leaders need to create a whole new game plan. In this white paper we’ll discuss the keys to sales force design for CAR T therapies and describe how they differ from the strategy behind sales force design for traditional therapies.

To effectively promote orphan drugs, life sciences companies must get creative to follow rare disease patients’ winding journeys to diagnosis and treatment. We explore how companies can perform thorough investigations to more effectively match therapies up with patients.

Life sciences companies spend years researching, developing and testing therapies that offer exciting new possibilities for treatment. But it’s often the launch – that short time frame between R&D and product uptake – that determines whether the therapy will fly or flop. This white paper outlines how data-driven commercial operations help ensure long-term commercial success.